Fas/FasL-mediated apoptosis and inflammation are key features of acute human spinal cord injury: implications for translational, clinical application

Wen Ru Yu · Michael G. Fehlings

Received: 8 July 2011 / Revised: 28 September 2011 / Accepted: 29 September 2011 / Published online: 29 October 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract The Fas/FasL system plays an important role in apoptosis, the inflammatory response and gliosis in a variety of neurologic disorders. A better understanding of these mechanisms could lead to effective therapeutic strategies following spinal cord injury (SCI). We explored these mechanisms by examining molecular changes in postmortem human spinal cord tissue from cases with acute and chronic SCI. Complementary studies were conducted using the in vivo Fejota™ clip compression model of SCI in Fas-deficient B6.MRL-Fas-lpr (lpr) and wild-type (Wt) mice to test Fas-mediated apoptosis, inflammation, gliosis and axonal degeneration by immunohistochemistry, Western blotting, gelatin zymography and ELISA with Mouse 32-plex cytokine/chemokine panel bead immunoassay. We report novel evidence that shows that Fas-mediated apoptosis of neurons and oligodendrocytes occurred in the injury epicenter in all cases of acute and subacute SCI and not in chronic SCI or in control cases. We also found significantly reduced apoptosis, expression of GFAP, NF-κB, p-IKappaB and iba1, increased number of CD4 positive T cells and MMP2 expression and reduced neurological dysfunction in lpr mice when compared with Wt mice after SCI. We found dramatically reduced inflammation and cytokines and chemokine expression in B6.MRL-Fas-lpr mice compared to Wt mice after SCI. In conclusion, we report multiple lines of evidence that Fas/FasL activation plays a pivotal role in mediating apoptosis, the inflammatory response and neurodegeneration after SCI, providing a compelling rationale for therapeutically targeting Fas in human SCI.

Keywords Fas/FasL · Apoptosis · Inflammation · Cytokine/chemokine · SCI

Introduction

Spinal cord injury (SCI) causes the shearing of cell membranes and axons, disruption of the blood–spinal cord barrier, cell death, immune cell transmigration, and myelin degradation [4–7, 9, 34]. It also triggers a cascade of secondary damage including vascular permeability, infiltration of peripheral inflammatory cells, activation of astrocytes and microglia, release of pro-inflammatory mediators, demyelination and axonal damage [37] which progressively destroys an increasing amount of tissue adjacent to the primary lesion [5, 14, 27, 38]. The death receptor Fas and its specific ligand (FasL) have gained widespread recognition as an apoptotic mediator [11, 12, 15–17, 20, 32, 33] for inducing inflammation by release of pro-inflammatory cytokines [26, 39], causing the migration of neutrophils and macrophages to injury site [17, 31] and being involved in T cell proliferation [28] following SCI as well as maintaining the immune suppressed status in the normal brain. Fas deficiency [11, 44, 45], competitive inhibition of Fas activation, or neutralization of FasL with an anti-FasL antibody can promote neurobehavioral recovery in animal models of stroke, SCI [1, 16, 45] and cervical spondylotic myelopathy [46].
Neutralization of FasL also reduces the initial infiltration of inflammatory cells, creating an inflammatory response that facilitates recovery of locomotor function after SCI [31]. A better understanding of these mechanisms could lead to effective therapeutic strategies following SCI.

In this study, we investigated, for the first time, the importance of the Fas/FasL system in the regulation of neuronal and glial apoptosis, inflammatory cell infiltration, gliosis and axonal regeneration following human SCI. We examined the molecular changes in postmortem human spinal cord tissue after acute, subacute and chronic SCI. To provide a mechanistic basis for these observations, complementary investigations were undertaken in a clinically relevant murine model of SCI using mutant mice deficient in Fas expression. Our results clarify the importance of Fas/FasL in the pathobiology of human SCI thus providing a strong case for targeting Fas therapeutically in this devastating clinical condition.

Materials and methods

Human SCI

Sections of paraffin tissue with 5 μm thickness were retrieved from the Spinal Cord Tissue Bank (Table 1: 16 cases of SCI and 6 controls) in the pathology department, University Health Network, Toronto, Canada for Hematoxylin and Eosin and Luxol Fast Blue (H&E/LFB) staining and immunohistochemistry.

Immunohistochemical analysis in human SCI

After being deparaffinized, sections were treated with microwave in 10 mM citrate buffer, 0.3% H₂O₂, avidin solution and blocked with 1% BSA and 5% nonfat milk with 0.3% Triton X-100 for 1 h. The following primary antibodies were used in this study: anti-Fas and anti-FasL (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) for cell death receptor, activated caspase-3 (1:200, Cell Signaling Technology, Beverly, MA); activated caspase-9 and caspase-7 (1:150; 1:1,500 Nov Littleton, CO 80160, USA) for apoptosis, anti-PG-M1 (CD68 for phagocytic macrophages of microglial and monocytic: 1:50, Dako, Glostrup, Denmark), anti-ionized calcium binding adaptor molecule 1 (Iba1) for ramified and activated microglia (I:300, Wako pure Chemical Industries, Lid); anti-CD3 (1:200, Dako, Denmark) for the human mature T lymphocytes; anti-CD45 (1:500, BD) for B lymphocytes, anti-MPO (1:50, Dako, Denmark) for oxidative reactivity, and MMP-9 (1:100, Chemicon), a pro-inflammatory protease, in blocking solution overnight at 4°C. Following extensive

| Case | Age | Sex | Group | Time between injury and death | Level of injury | Cause of injury |
|------|-----|-----|-------|-------------------------------|----------------|----------------|
| 1    | 73  | M   | Acute | 2 weeks                       | C1-2           | Fall           |
| 2    | 86  | M   | Acute | 3 weeks                       | C1-2           | Fall           |
| 3    | 37  | M   | Acute | 4 weeks                       | C4-5           | Fall           |
| 4    | 82  | M   | Subacute | 5 weeks                     | C5-6           | Sports injury  |
| 5    | 68  | M   | Subacute | 5 weeks                     | C7             | MVA            |
| 6    | 29  | M   | Subacute | 7 weeks                     | T12            | Fall           |
| 7    | 68  | F   | Subacute | 2 months                    | T5             | Fall           |
| 8    | 67  | M   | Subacute | 3.5 months                  | C2-3           | Fall           |
| 9    | 43  | F   | Subacute | 3.5 months                  | C5-6           | MVA            |
| 10   | 66  | M   | Chronic | 6 months                    | C5-6           | Fall           |
| 11   | 31  | F   | Chronic | 8 months                    | C2-3           | MVA            |
| 12   | 19  | M   | Chronic | 2 years                     | C4/5           | Sports injury  |
| 13   | 65  | M   | Chronic | 3.5 years                   | C1-2           | MVA            |
| 14   | 69  | M   | Chronic | 15 years                    | C6/7           | Diving accident|
| 15   | 42  | M   | Chronic | 24 years                    | C3/4           | MVA            |
| 16   | 45  | M   | Chronic | 24 years                    | C5/6           | Sports injury  |
| 17   | 43  | F   | Control | N/A                         | N/A            | N/A            |
| 18   | 36.8| F   | Control | N/A                         | N/A            | N/A            |
| 19   | 41.7| F   | Control | N/A                         | N/A            | N/A            |
| 20   | 81.5| M   | Control | N/A                         | N/A            | N/A            |
| 21   | 55  | F   | Control | N/A                         | N/A            | N/A            |
| 22   | 44  | M   | Control | N/A                         | N/A            | N/A            |
rinsing in 0.1 M PBS, sections were incubated in biotinylated goat anti-mouse or anti-rabbit antibody (diluted 1:200, Vector Laboratories CA, USA) for 1 h at room temperature. After incubation with the biotinylated secondary antibody, the avidin–biotin complex (ABC; VECTASTAIN® ABC reagent prepared in advance as described in the kit instructions) and diaminobenzidine (DAB; DAB Peroxidase Substrate Kit, Vector Laboratories) were applied to the sections for visualization of the reaction product. Sections from six nonSCI patients (age-matched) were used as normal controls. For negative controls, the primary antibody was omitted or incubated with isotype-matched antibodies (1:100–1:10,000; IgG).

Analysis of apoptosis for Human SCI

Spinal cord sections were processed for TUNEL labeling (ApopTag®) plus a peroxidase in situ apoptosis detection kit (Chemicon Biotechnology Inc, Temecula, CA), as previously described [13].

In vivo spinal cord injury

SCI was performed by the Fejota™ clip compression technique at T5/6 [24, 25] with 8.3 g clip for 1 min in 8-week-old female wild-type (Wt) and B6.MRL-Fas-lpr (lpr) mice bought from Jackson Laboratory, Bar Harbor, Maine, as previously described. All protocols were in accordance with the Canadian Council of Animal Care policies and were approved by the animal care committee of the University Health Network.

**Biotinylated dextran amine (BDA) tracing of the corticospinal tract (CST) and BDA staining**

To trace the corticospinal tract, Wt and lpr mice (n = 4/group) were anesthetized and had their fur removed by shaving after 8 weeks post-injury. The scalp was incised and the skull overlying the sensorimotor cortex was carefully removed with a dental drill. BDA (molecular weight of 10,000) was injected into right sensorimotor cortex with a total of 0.5 μl per sample of sham controls, and 3, 14 and 70 days (n = 7 per group) after SCI in MicroCon.
centrifugation tubes (Millipore) was sent to Eve technology company using the Mouse 32-plex cytokine/chemokine panel Bead Immunoassay. The protein concentrations of 32 chemokines/cytokines were quantified and then analyzed using repeated measures ANOVA and \( t \) tests using the SPSS SigmaStat 3.0 statistical package (Aspire Software International, Leesburg, VA).

Zymography

Zymogram gels consisted of 7.5% polyacrylamide (native) gel polymerized together with gelatin (1 mg/ml). After electrophoresis, the gels were washed twice with 2.5% Triton X-100 and incubated with substrate buffer (50 mM Tris, 5 mM CaCl\(_2\), pH 7.5) at 37°C for 24 h. The zymogram is subsequently stained (commonly with coomassie brilliant blue), and areas of digestion appear as clear bands against a darkly stained background where the substrate has been degraded by the enzyme. Gelatinolytic of MMPs activities were detected as transparent bands on the blue background and quantified using Gel Pro analysis software (Media Cybernetics, Silver Spring, MD).

Behavioral tests

All behavioral tests were performed by two independent observers in a double-blind manner weekly for 8 weeks after SCI and assessed using the Basso Mouse locomotor rating Scale (BMS) [3].

Cell quantification

All digital images were captured, in a double-blind manner, from four random fields per section in the injured epicenter of the cross-sections in human SCI and control cases using a Nikon Eclipse E800 light microscope and in Wt and lpr mice using a Zeiss LSM 510 META confocal laser scanning fluorescence microscope. The images were taken at 20× magnification for CD68, TUNEL, F4/80 and CD4 positive cell counting. We counted digital images of CD68, TUNEL and F4/80 positive cells using ImageJ software (developed at the National Institute of Health, Bethesda, MD). Values from four random fields were averaged to a single value per case or per animal. The results were expressed as the number of CD68, TUNEL and F4/80 positive cells.

Statistical analysis

Significant differences in cell counts were analyzed using repeated measures ANOVA and \( t \) test using the SPSS statistical package as before. All data are expressed as mean ± SD. The criterion for significance was set at \( p < 0.05 \).

Results

The characteristics of the human SCI subjects are outlined in Table 1. The age range was 19–86 and the time between injury and death ranged from 2 weeks to 24 years.

Fas-mediated inflammatory response after human SCI

To determine the role of FasL in the modulation of immune reactions involving inflammation, we examined the inflammatory response following human SCI using immunohistochemistry with CD68. We observed a moderate to marked increase in the number of CD68 positive microglia/macrophages, which showed features typical of activated microglia/macrophages including small, round shapes, occurring at 2 weeks (Fig. 1b, k), 3 weeks, 4 weeks (acute SCI: 2–4 weeks as see Table 1) and 3.5 months (subacute: 5 weeks to 3.5 months) (Fig. 1c–e) after SCI. However, the number of CD68 positive microglia/macrophages was decreased at 6 months (Fig. 1f) and 8 months (chronic SCI: over 6 months) (Fig. 1g) post-SCI when compared to 3 weeks (Fig. 1c), 4 weeks (Fig. 1d) and 3.5 months (Fig. 1e). There was a small number of activated microglia and many cells with ramified morphology in the epicenter of the SCI at 2 years and 17 years (Fig. 1h, i) after SCI and control spinal cords (Fig. 1a, j). The number of CD68 positive microglia/macrophages was significantly greater in the compressed epicenter of SCI when compared with normal spinal cords (\( p = 0.003 \), Fig. 1l). As illustrated in Fig. 2b, we found many MMP9 positive cells in the epicenters of spinal cord in acute and subacute SCI but not in control or chronic SCI cases. Moreover, we observed numerous cells which expressed MPO (Fig. 2c), a marker of neutrophils, distributed in the spinal cord parenchyma.

Increased lymphocytic infiltration in the injured human SCI

There was a scattered distribution of CD3 and CD45 positive cells in blood vessels in control and chronic SCI cases. Moreover, in contrast to control cases, there were also numerous CD45 and CD3 positive cells (Fig. 2d, e) randomly distributed in the spinal cord epicenter parenchyma following acute and subacute SCI.

Apoptosis after human SCI

In investigating whether SCI-induced apoptosis occurred by activated caspase-3 and TUNEL as complementary markers of apoptosis (Fig. 3), we observed that most cells which were positive for activated caspase-3 (Fig. 3b, c) or TUNEL (Fig. 3k, l) were randomly distributed in the
epicenter of SCI lesions from 2 weeks to 3.5 months following SCI but not in control cases or following chronic SCI (Fig. 3a, j) and caudal regions of SCI spinal cords. We found activated caspase-3 positive oligodendrocytes (Fig. 3d), neurons, neutrophils (Fig. 3e) and microglia/macrophages (Fig. 3f) in the injured epicenter of SCI. To look specifically at the apoptotic pathway, we examined the involvement of mitochondria by assessing the activation of caspase-9 and caspase-7 which are downstream targets of this pathway. We found that activated caspase-9 (Fig. 3g) and caspase-7 (Fig. 3h) were expressed on neurons and glial cells after acute SCI. No significant increase in the number of CD68 positive microglia/macrophages (l) in the epicenter of acute SCI and subacute SCI when compared to control (a) and chronic SCI (f 6 months, g 8 months, h 2 years and i 17 years).

Fas/FasL accumulation in the epicenter of human SCI lesions

To test whether spinal cord injury induces Fas/FasL accumulation, we performed immunohistochemistry with
anti-Fas and FasL antibodies. We only found a few Fas or FasL positive cells in control spinal cords (Fig. 4a, d) and in chronic SCI. However, we observed a lot of Fas or FasL positive glial cells (Fig. 4b, e) and neurons (Fig. 4c, f) in injured epicenters in acute and subacute SCI when compared with control cases and chronic SCI. Using double staining with Fas or FasL antibodies and cell-specific markers, Fas or FasL immunoreactivity was expressed in neurons, astrocytes and microglia/macrophages in the injured epicenter after SCI.

Fas/FasL-mediated apoptosis and inflammation in human SCI

To confirm that Fas/FasL expression is associated with apoptotic cell death and inflammation, we first performed double-labeling activated caspase-3 with anti-Fas or anti-FasL antibodies. We identified the Fas or FasL positive activated caspase-3 (Fig. 4g, h) in the injured epicenter after SCI. Examining Fas/FasL-mediated inflammation using double-labeling CD68 and MPO with Fas and FasL antibodies, we found Fas or FasL positive macrophages (Fig. 4i, j), astrocytes (Fig. 4k) and neutrophils (Fig. 4l) in the injured epicenter after acute and subacute SCI.

Fas-deficient mice exhibit reduced GFAP expression after SCI

To confirm the Fas/FasL-mediated inflammation as seen in human SCI, we used immunohistochemistry and Western blotting with GFAP antibody, we observed an increase in GFAP expression after SCI in both lpr mice (Fig. 5c) and Wt mice (Fig. 5b) at 7–70 days post-SCI but not in sham controls (Fig. 5a). However, lpr mice showed a marked attenuation in the expression of GFAP at 3 (p = 0.003) and 14 (p = 0.012) days post-SCI compared with Wt mice as determined by Western blot analysis (Fig. 5d).

Fas-deficient mice exhibit reduced inflammatory cell infiltration after SCI

To confirm the Fas/FasL-mediated inflammation as seen in human SCI, we used immunostaining with microglia/macrophages (Iba1) and macrophages (F4/80) antibodies following SCI in lpr and Wt mice. We found many Iba1 positive cells with larger, rounded, and short processes, typical of activated macrophages in the degenerated white matter of spinal cords, after SCI from 7 to 70 days in both lpr and Wt mice when compared to sham control (Fig. 5e). There was a significant increase in the number of F4/80 positive macrophages at the injured epicenter of SCI in lpr mice when compared with the Wt mice at 3 (p = 0.003), 7 (p = 0.012) and 70 days post-SCI (not shown). Of note, lpr mice had significantly decreased numbers of short ramified microglia surrounding the injured epicenter when compared with Wt mice in sagittal section using immunostaining with Iba1 antibody (not shown).
shown). Furthermore, Western blot analysis with Iba1, NF-κB and p-IKappaB antibodies showed that there was a significant decrease in the level of Iba1 expression at 3 (\(p = 0.043\)) and 7 (\(p = 0.004\)) days (Fig. 5h, j), NF-κB expression at 3 (\(p = 0.002\)) and 14 days (\(p = 0.019\)) (Fig. 5h, k) and p-IKappaB expression (which plays a key role in regulating the immune response to infection) at 7 (\(p = 0.024\)), 14 and 70 days (\(p = 0.004\)) (Fig. 5i, l) in lpr mice when compared with the Wt mice after SCI, respectively. Moreover, there was significant elevation of MMP2 activation (Fig. 5m, n) in lpr mice when compared with the Wt mice at 7 days post-SCI but not MMP9 activation.

Fas-deficient mice exhibit increased CD4 positive lymphocytes after SCI

Given that Fas/FasL-mediated apoptosis appears to be closely linked with the immune response to trauma, we analyzed the expression of immune cells. Of note, we observed that there was a significantly increased number of CD4 positive lymphocytes present in the injured spinal
cord at 7 and 14 days after SCI in lpr mice relative to Wt mice (Fig. 6a–c).

Fas-deficient mice exhibit increased the levels of anti-inflammatory cytokines and reduced pro-inflammatory cytokines after SCI. There is a correspondence between the extent of microglia/macrophage reactivity and the elevation of inflammatory cytokines inducing lymphocyte proliferation and neuroinflammatory response after SCI. Using ELISA with Mouse 32-plex cytokine/chemokine panel bead immunoassay, we found significantly increased the levels of anti-inflammatory cytokine IL-10 and IL-7 (Fig. 6d, e) expression at 3 days and reduced levels of pro-inflammatory cytokines IL-1alpha, IFN gamma and IL-15 (Fig. 6g–i) at 14 days and IL-6 at 3 days (Fig. 6j) after SCI in lpr mice when compared with Wt mice. We also found a significant increase in the levels of pro-inflammatory cytokines of IL-1alpha, IL-15 and IL-12p40 at 14 days (Fig. 6g, i, k) and IL-6 at 3 days (Fig. 6j) after SCI when compared with sham control in Wt mice.
Fas-deficient mice exhibit reduced chemokines after SCI

The chemokines are involved in a wide variety of processes including acute and chronic types of inflammation and infectious diseases. To confirm Fas/FasL-mediated inflammation involved chemokines after SCI, we used an ELISA with Mouse 32-plex cytokine/chemokine panel bead immunoassay and found a significant increase in the levels of chemokines of MCP-1 (monocyte chemoattractant protein-1: Fig. 7a), Eotaxin (Fig. 7b), RANTES/CCL5 (regulated upon activation, normal T-cell expressed and secreted: Fig. 7c), MIG (Monokine induced by IFN gamma (Fig. 7d), MIP-1α (macrophage inflammatory protein-1α: Fig. 7e) at 14 days after SCI.
post-SCI. MIP-2 (Fig. 7f) and M-CSF (Macrophage colony-stimulating factor) from 3 or 14 to 70 days post-SCI when compared with sham control in Wt mice. Moreover, we found significantly reduced levels of chemokines MCP-1 and Eotaxin (Fig. 7a, b) at 14 days after SCI in lpr mice when compared with Wt mice after SCI. We did not find any differences in G-CSF, IL-1ß, IL-2, IL-9 and VEGF between lpr and Wt mice after SCI. Moreover, the standard range was exceeded for IL-3, IL-4, IL-5, IL-12p70, ILX, TNF-α, and GM-CSF (not shown) following SCI in both lpr and Wt mice.

Changes for BDA labeling CST

To investigate Fas-mediated inflammation in axon regeneration, we examined the long-term outcome and pathology of spinal-injured animals in lpr and Wt mice. Sagittal sections containing the lesion revealed prominent BDA labeling of the main CST in the dorsal column and extensive collaterals in the gray matter rostral to the injury (Fig. 8a, b). BDA-labeled axons ended just rostral to the injury site in lpr mice but ended further from the injured site in Wt mice.

Western blotting results

There was significantly increased β-III tubulin and NF200 expression at 3, 14 and 70 days post-SCI (Fig. 8c–e) and elevation of axonal growth-associated protein MMP2 expression at 7 and 14 days (Fig. 5i, j) post-SCI. Upregulation with chemokine (KC) expression (Fig. 8f, g) was associated with axonal growth at 14 and 70 days post-SCI.
when compared with sham controls in lpr mice. There were also no significant differences in MAP2, CNPase and MBP expression (Fig. 8i, j) as assessed by Western blotting with MAP2, CNPase and MBP antibodies.

Fas-deficient mice exhibit decreased neurological dysfunction after SCI

To determine if the increased β-III tubulin and NF200 expression in the lpr mice would support improved functional recovery, the mice were tested using the BMS open field locomotor test and compared with Wt mice. A normal BMS score for mice, before injury, is 9. The locomotor performance of the lpr mice was consistently better than that of the Wt mice (p = 0.001). These significant differences were retained until the end point of evaluation in BMS scores of both groups at 70 days post-SCI (Fig. 8k). The average score of the lpr mice at 70 days was 3.087 ± 0.191, while the average score of the Wt mice over the same time points was 1.583 ± 0.204.

Discussion

We report novel evidence showing a role for Fas/FasL in apoptosis of neurons and oligodendrocytes and the inflammatory response in human SCI. To provide a mechanistic basis for these findings, we determined that Fas-deficient mice with SCI exhibit a significant reduction in the infiltration of inflammatory cells (microglia/macrophages), reduction in the level of GFAP and p-IKappaB expression and release of cytokines and chemokines as compared with Wt controls. Importantly, recovery of locomotor function is facilitated in Fas-deficient mice when compared with Wt mice after SCI. These data strongly suggest that targeting the Fas pathway is an attractive therapeutic target following SCI.

A growing body of evidence indicates that Fas-mediated neuronal and oligodendrocyte apoptosis and inflammation contribute to demyelination and Wallerian degeneration, and thereby affect neuronal function and survival, in the pathobiology of SCI [1, 2, 5, 12, 16, 19, 41, 44]. We and others have shown that neuronal, oligodendrocyte and microglia apoptosis, through activation of the Fas death receptor pathway is a key event [12, 15, 16, 43, 44, 47] following SCI in animal models. Davis reported that SCI resulted in FasL and Fas translocation into membrane raft microdomains where Fas associates with the adaptor proteins Fas-associated death domain, caspase-8, cellular FLIP long form, and caspase-3, forming a death-inducing signaling complex [15]. Fas deficiency [11, 44], the application of soluble Fas receptor [1] and neutralization of...
endogenous FasL [16, 45] have decreased apoptosis and improved functional recovery. The increased expression of Fas and FasL after SCI [12, 16, 44, 47] results in the continued activation of microglia and the inflammatory response to injury, inducing a cascade of apoptotic cell death [4], contributing to demyelination and Wallerian degeneration and thereby affecting neuronal function and survival. Consistent with previous findings that oligodendrocyte and neuronal apoptosis was detected in Wallerian degenerating areas at 6 h to 3 weeks post-injury in animal models and in a lesion epicenter from 0–3.5 months following humans SCI, we demonstrated an increased caspase-3, 7 and 9 activation, TUNEL, Fas and FasL positive cells in injured epicenter following human acute and subacute SCI but not in chronic SCI or in control cases. We report new evidence that confirms Fas/FasL-mediated apoptosis and which shows Fas/FasL co-localization with activated caspase-3 in the injured epicenter of SCI suggesting Fas-mediated apoptosis plays an important role in neuronal degeneration following SCI. Thus these data

Fig. 8 Fas-deficient mice show reduced axonal degeneration and neurological dysfunction following SCI. BDA-labeled CST axons ended just rostral to the injury site in lpr mice (a) but further away in relation to the injured site in Wt mice (b). We found elevated expression of NF200 (c), β-III tubulin (d, e) and growth-associated chemokines (f P-10, g KC, and h LIF) in lpr mice when compared with Wt mice. However, we no found difference in CNPase (i) and MAP2 (j) expression as assessed by Western blotting with CNPase and MAP2 antibodies. There is a significant difference in BMS scale (k) between lpr mice and Wt mice.
provide evidence that the functional neurological deficits after SCI are associated with loss of neurons, oligoden-
drocytes, and demyelination.

SCI elicits an inflammatory response involving resident microglia and infiltration of neutrophils, monocytes/mac-
rophages, and lymphocytes into the lesion from the systemic immune system [22, 35]. Activated microglia/
macrophages were found in the spinal cord from 5 days to 4 months [10] and a year after human SCI [21]. We pro-
duced similar results which show that activated microglia/
macrophages were the predominant inflammatory cell type in all cases of SCI from 2 weeks to 6 months at injured
epicenter but not in rostral and caudal regions following human SCI. We also found co-localization of Fas/FasL on
macrophages, neutrophils and astrocytes in the epicenter of SCI suggesting Fas-mediated inflammation following
human SCI.

The inflammatory response may be beneficial, reflecting the role of inflammation as a host defense response to
injury and promoting the regeneration of surviving neurons or it may release toxic factors that amplify tissue damage
which can lead to poor functional recovery following SCI [37]. Letellier et al. [31] reported that lack of FasL on CNS
resident neural cells reduces the initial infiltration of inflammatory cells, creating an inflammatory response after
SCI. However, the molecular mechanism by which Fas induces inflammation has remained elusive. To further con-
firm Fas/FasL-mediated apoptosis and inflammation occurring in human SCI, we used the Fejota™ clip com-
presision model of SCI in vivo in lpr and Wt mice at 8 weeks. Consistent with previous finding in our own research
and that of others, there was a significantly reduced level of caspase-3 and 9 activation following SCI in lpr mice relative to Wt mice [11]. In the present study, we present new findings showing a reduction of GFAP, iba1, NF-xB and p-IKappaB expression and activated microglia in the injury epicenter and decreased neurologi-
cal dysfunction following SCI in lpr mice relative to Wt mice. These results suggest that Fas has the potential to reduce the extent of secondary damage by interacting with microglia and leukocytes in the following ways: (1) inhibiting microglia activation thereby reducing pro-
inflammatory cytokine production resulting in restricted neutrophil infiltration and suppressed inflammatory
responses. (2) inhibiting GFAP expression which promotes axonal regeneration as we found a significant increase in
levels of NF200 and β-III tubulin and improved neuro-
logical function recovery in lpr mice relative to Wt mice following SCI. (3) increasing MMP-2 promoted functional
recovery after injury by regulating the formation of glial saddles and whitematter sparing and/or axonal plasticity
[23]. These findings provide a better understanding of the inflammatory mechanisms after SCI. The results further
suggest that neutralization of Fas reduces the initial infil-
tration of inflammatory cells and apoptosis, creating an
inflammatory response that facilitates recovery of loco-
motor function after SCI. There are conflicting results
relating to the lack of Fas on CNS resident neural cells
reducing apoptosis and improving neurological function
recovery in lpr mice following SCI. We [11] and others
[44] have shown that Fas deficiency and competitive
inhibition of Fas activation [1] can reduce apoptosis [45]
and promote neurobehavioral recovery in animal models
of SCI. In contrast, Letellier et al. [31] reported that Fas
deficient mice do not show decreased caspase-3 activity or
improved functional recovery following SCI. There are
several factors contributing to these conflicting results in
lpr mice following SCI. First, Letellier et al. [31] used Fas-
floxed mice with a Nestin-Cre background at 17.5 weeks.
lpr mice develop a lymphoproliferative disorder at ages
greater than 18 weeks. In contrast, we used B6.MRL-Fas-
lpr mice with a C57Bl/6 J background at 8 weeks of age to
avoid this potentially confounding feature, which develops
later and less severely in this strain [42]. Second, we used a
different model of SCI to Letellier which could contribute
to differing results.

Pro-inflammatory cytokines/chemokines are strongly
implicated in regulating neutrophil infiltration [18]. Lac-
roix reported that enhanced IL-6 signaling after SCI results
in a sixfold increase in neutrophil infiltration and expanded
the neural damaged area [30]. The administration of a
mixture of pro-inflammatory cytokines (IL-1b, IL-6, and
TNFa) at the acute phase of SCI has been shown to pro-
voke an increase in the recruitment of leukocytes to the
lesion site [29]. The rise of cytokines is transient from
15 min to 5 days as levels return to base level after spinal
cord injury in rats, humans and mice thus establishing the
fact that a short lived burst of inflammatory cytokines is a
feature of SCI across several species [29, 36, 40]. A sys-
tematic study that documents the acute and chronic
evolution of families of inflammatory molecules is lacking.
In the present study, to test the release of pro-inflammatory
mediator (cytokines and chemokines) as regulators of the
infiltration of leukocytes and macrophages into the injured
spinal cord, we analyzed the release of cytokines and
chemokines in sham controls, 3, 14 and 70 days following
SCI in lpr and Wt mice. We first reported on 32 cytokine
and chemokines derived from same sample and from dif-
ferent time points following SCI in both lpr and Wt mice.
Importantly, we show a significant increase of inflamma-
tory mediators: cytokines (IL-1α, IL-12p40, IL-7 and
IL-15 at 14 days and IL-7 and IL-13 at 70 days) in Wt
mice after SCI. The rise of chemokines lasts even longer
than that of cytokines from 3 to 70 days after spinal cord
injury in both lpr and Wt mice. Our results show reduced
chemokine expression and increased anti-inflammatory
cytokines IL-10 may be contributing to better BMS score in lpr mice than Wt mice following SCI. These findings are consistent with Bethea [8] who reported that systemically administered interleukin-10 reduces tumor necrosis factor-α production significantly improves functional recovery following traumatic SCI in rats.

In conclusion, we report novel evidence showing that Fas/FasL-mediated apoptosis of neurons and oligodendrocytes and inflammation contributes to the pathobiology of spinal cord degeneration and affects neuronal function and survival in human SCI. Fas-deficient mice exhibit significantly reduced infiltration of inflammatory cells (microglia/macrophages), the level of GFAP and p-IKappaB expression and release of cytokines and chemokines which facilitates recovery of locomotor function when compared with Wt mice following SCI. This work provides a compelling rationale for therapeutically targeting Fas in human SCI.

Acknowledgments This work was supported by the Krembil Chair in Neural Repair and Regeneration. The authors would like to thank Dr. Madeleine O’Higgins for her valuable comments, editing and feedback and Jian Wang for BDA injection.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Ackery A, Robins S, Fehlings MG (2006) Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 23:604–616
2. Agrawal S, Gupta S (1999) Increased activity of caspase-3 and caspase-8 in anti-Fas-induced apoptosis in lymphocytes from ageing humans. Clin Exp Immunol 117:285–290
3. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McGugue DM, Popovich PG (2006) Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 23:635–659
4. Beatte MS (2004) Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol Med 10:580–583
5. Beatte MS, Hermann GE, Rogers RC, Bresnahan JC (2002) Cell death in models of spinal cord injury. Prog Brain Res 137:37–47
6. Bethea JR (2000) Spinal cord injury-induced inflammation: a dual-edged sword. Prog Brain Res 128:33–42
7. Bethea JR, Dietrich WD (2002) Targeting the host inflammatory response in traumatic spinal cord injury. Curr Opin Neurol 15:355–360
8. Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, Loo K, Green J, Dietrich WD (1999) Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 16:851–863
9. Blight AR (1985) Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 2:299–315
10. Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, Brook GA (2007) Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurol 7:17
11. Casha S, Yu WR, Fehlings MG (2005) FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury. Exp Neurol 196:390–400
12. Casha S, Yu WR, Fehlings MG (2001) Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 103:203–218
13. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW, Dawson TM, Dawson VL, Park DS, Kroemer G, Slack RS (2002) Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 158:507–517
14. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beatte MS (1997) Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 3:73–76
15. Davis AR, Lotocki G, Marcillo AE, Dietrich WD, Keane RW (2007) FasL, Fas, and death-inducing signaling complex (DISC) proteins are recruited to membrane rafts after spinal cord injury. J Neurotrauma 24:823–834
16. Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M, Edler L, Krammer PH, Martin-Villalta A (2004) Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 10:389–395
17. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK (2003) Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 5:118–125
18. Donnelly DJ, Popovich PG (2008) Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 209:378–388
19. Emery E, Aldana P, Bunge MB, Puckett W, Srivivasan A, Keane RW, Bethea J, Levi AD (1998) Apoptosis after traumatic human spinal cord injury. J Neurosurg 89:911–920
20. Felderhoff-Mueser U, Taylor DL, Greenwood K, Kozma M, Stibenz D, Jouoshi UC, Edwards AD, Mehmet H (2000) Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 10:17–29
21. Fleming JC, Norengen MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles M, Dietrich WD, Weaver LC (2006) The cellular inflammatory response in human spinal cords after injury. Brain 129:3249–3269
22. Hausmann ON (2003) Post-traumatic inflammation following spinal cord injury. Spinal Cord 41:369–378
23. Hu SY, McKeon R, Goussev S, Werb Z, Lee JU, Trivedi A, Noble-Haeusslein LJ (2006) Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 26:9841–9850
24. Joshi M, Fehlings MG (2002) Development and characterization of a novel, graded model of clip compressive spinal cord injury in rats. J Neurotrauma 23:604–616
25. Joshi M, Fehlings MG (2002) Development and characterization of the mouse: Part 2. Quantitative neuroanatomical assessment and analysis of the relationships between axonal tracts, residual tissue, and locomotor recovery. J Neurotrauma 19:191–203
26. Kang SM, Hoffmann A, Le D, Springer ML, Stock PG, Blau HM (1997) Immune response and myoblasts that express Fas ligand. Science 278:1322–1324
27. Keane RW, Kraydieh S, Lotocki G, Bethea JR, Krajewski S, Reed JC, Dietrich WD (2001) Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J Neuropathol Exp Neurol 60:422–429
28. Kennedy NJ, Kataoka T, Tschopp J, Budd RC (1999) Caspase activation is required for T cell proliferation. J Exp Med 190:1891–1896
29. Klusman I, Schwab ME (1997) Effects of pro-inflammatory cytokines in experimental spinal cord injury. Brain Res 762:173–184
30. Lacroix S, Chang L, Rose-John S, Tuszynski MH (2002) Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol 454:213–228
31. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, Konecki K, Klussmann S, Corsini NS, Kleber S, Drost N, Neumann A, Levi-Strauss M, Brors B, Grett N, Edler L, Fischer C, Hill O, Thiemann M, Biglari B, Karray S, Martin-Villalba A (2010) CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 32:240–252
32. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809–3817
33. Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L, Hirt L, Waebier C, Hyman BT, Yuan J, Meskowitz MA (2000) Fas receptor and neuronal cell death after spinal cord ischemia. J Neurosci 20:6879–6887
34. Popovich PG, Stuckman S, Gienapp IE, Whitacre CC (2001) Alterations in immune cell phenotype and function after experimental spinal cord injury. J Neurotrauma 18:957–966
35. Popovich PG, Wei P, Stokes BT (1997) Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 377:443–464
36. Rice T, Larsen J, Rivest S, Yong VW (2007) Characterization of the early neuroinflammation after spinal cord injury in mice. J Neuropathol Exp Neurol 66:184–195
37. Rolls A, Shechter R, Schwartz M (2009) The bright side of the glial scar in CNS repair. Nat Rev Neurosci 10:235–241
38. Schwab ME, Bartholdi D (1996) Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 76:319–370
39. Seino K, Kayagaki N, Takeda K, Fukao K, Okumura K, Yagita H (1997) Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113:1315–1322
40. Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT (1998) Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 152:74–87
41. Takagi T, Takayasu M, Mizuno M, Yoshimoto M, and Yoshida J (2003) Caspase activation in neuronal and glial apoptosis following spinal cord injury in mice. Neurrol Med Chir (Tokyo) 43:20–29 (discussion 29–30)
42. Vidal S, Kono DH, Theofilopoulos AN (1998) Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J Clin Invest 101:696–702
43. Yamaura I, Yone K, Nakahara S, Nagamine T, Baba H, Uchida K, Komiyama S (2002) Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression. Spine 27:21–26
44. Yoshino O, Matsuno H, Nakamura H, Yudoh K, Abe Y, Sawai T, Uzuki M, Yonehara S, Komura T (2004) The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine 29:1394–1404
45. Yu WR, Liu T, Fehlings TK, Fehlings MG (2009) Involvement of mitochondrial signaling pathways in the mechanism of Fas-mediated apoptosis after spinal cord injury. Eur J Neurosci 29:114–131
46. Yu WR, Liu T, Kiehl TR, Fehlings MG (2011) Human neuro-pathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Brain 134:1277–1292
47. Zurita M, Vaquero J, Zurita I (2001) Presence and significance of CD-95 (Fas/APO1) expression after spinal cord injury. J Neurosurg 94:257–264